Pancuronium Bromide Injection Rx
Generic Name and Formulations:
Pancuronium bromide 1mg/mL, 2mg/mL; soln for IV inj; contains benzyl alcohol.
Various generic manufacturers
Indications for Pancuronium Bromide Injection:
Adjunct to general anesthesia to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Adults and Children:
Individualize. Adjunct to anesthesia: Initially 0.04 to 0.1mg/kg, then may use incremental doses starting at 0.01mg/kg. Relaxation for intubation: inject bolus dose of 0.06 to 0.1mg/kg. Neonates: give test dose 1st of 0.02mg/kg. Monitor with a peripheral nerve stimulator to avoid overdosage.
To be administered under the supervision of experienced clinicians. Have intubation, artificial respiration, oxygen therapy and reversal agents available. Myasthenia gravis or myasthenic (Eaton-Lambert) syndrome (do test dose and monitor). Pre-existing pulmonary disease. Renal disease or failure. Hepatic and/or biliary tract disease. Cardiovascular disease and edematous state. Long-term use in I.C.U. Immobilized for long periods. Severe obesity or neuromuscular disease; monitor airway and ventilation. Electrolyte imbalance. Adrenal cortical insufficiency. Neonates. Elderly. Pregnancy (Cat.C). Nursing mothers.
Prior administration of succinylcholine may potentiate effects (delay dose or give pancuronium 1st). Potentiated by volatile inhalational anesthetics (eg, enflurane, isoflurane, halothane), aminoglycosides, tetracyclines, bacitracin, polymyxin B, colistin, sodium colistimethate, magnesium salts. Significant additive effects with pancuronium bromide-metocurine and pancuronium bromide-d-tubocurarine combinations than with the individual drugs given alone. Potential severe ventricular arrhythmias in concomitant with tricyclics and halothane. Caution with quinidine injection.
Neuromuscular blocker (nondepolarizing).
Skeletal muscle weakness or prolonged paralysis, circulatory effects, salivation, transient rash; rare: hypersensitivity reactions.
Formerly known under the brand name Pavulon.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Triiodothyronine in the Treatment of Bipolar Depression
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Intranasal Oxytocin Reduces Negative Effects, Improves Cognitive Function in Schizophrenia
- E-Cigarettes Associated With More Harms Than Benefits at Population Level
- Examining Rates of Long-Term Opioid Use in Youth With Psychiatric Disorders
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Researchers Identify Novel Potential Biomarkers for Autism
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Personal Health Information Found in Recycling
- Nightmares in Military Personnel Frequently Comorbid With Mental Health Disorders
- Potential for SERMs as Adjunctive Therapy for Schizophrenia
- Addressing Racial Disparities in Bipolar Disorder Treatment
- Negative Symptoms Increase Cardiovascular Risk in Schizophrenia